以表观遗传调节器突变为基础的血栓预测模型,用于使用重复事件中的生存分析,对基本血栓细胞病患者的血栓预测模型
Pirun Saelue1, Patuma Sinthujaroen2, Supaporn Suwiwat2
1Hematology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand.
概括
患有IDH1突变的基本血栓塞动症 (ET) 患者面临更高的血栓形成风险. 普伦蒂斯,威廉和彼得森 (PWP) 间隙时间模型有效地预测了ET中的这些血栓事件.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 基本血小板血 (ET) 的特点是巨核细胞和血小板的过度生产,增加了血栓形成的风险.
- 确定影响ET血栓的遗传因素对于风险分层至关重要.
研究的目的:
- 评估与ET患者表观遗传调节器突变相关的血栓风险.
- 开发ET中血栓形成的预测模型.
主要方法:
- 一项对96名ET患者 (年龄大于15岁) 的队列研究,这些患者在2002年至2019年期间被诊断出患有ET.
- 下一代测序确定了25个向基因突变,包括驱动和表观遗传调节基因.
- 使用五种生存模型分析血栓事件,包括复发事件方法.
主要成果:
- 15名患者经历了17次动脉血栓事件,平均随访时间为6.91年.
- 在表观遗传调节器突变中,IDH1突变与100%的血栓事件频率有关.
- 在多变量分析中,IDH1突变成为血栓形成风险的重要预测因子.
结论:
- 普伦蒂斯,威廉和彼得森 (PWP) 间隙时间模型证明了ET中血栓形成的强有力的预测能力.
- IDH1突变是ET中血栓形成的重要风险因素,需要在更大的队列中进一步调查.
相关概念视频
Introduction To Survival Analysis
203
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
203
Assumptions of Survival Analysis
119
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
119
Actuarial Approach
71
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
71
Comparing the Survival Analysis of Two or More Groups
170
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
170
Cancer Survival Analysis
336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
Kaplan-Meier Approach
119
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
119


